Application of hydrangea paniculata extract in treatment of chronic kidney disease by regulating intestinal flora

A technology to regulate intestinal flora and panicle hydrangea, applied in the field of biomedicine, can solve problems such as inconsistent treatment effects and serious side effects

Pending Publication Date: 2021-09-07
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the drugs widely used in clinical treatment of chronic kidney disease are mainly chemotherapy drugs and various hormones or immunosuppress...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydrangea paniculata extract in treatment of chronic kidney disease by regulating intestinal flora
  • Application of hydrangea paniculata extract in treatment of chronic kidney disease by regulating intestinal flora
  • Application of hydrangea paniculata extract in treatment of chronic kidney disease by regulating intestinal flora

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 c-BSA (cationized-BSA, cationic albumin) induced chronic kidney disease model

[0058] 1. Antigen cationized BSA (C-BSA) preparation

[0059] Fraction V of natural bovine serum albumin: pure by electrophoresis, with an isoelectric point of 4.5, from Ameresco. Carbodiimide (EDC): Beijing Chemical Reagent Company. Anhydrous ethylenediamine (EDA): analytically pure, Beijing Chemical Reagent Company. Refer to the Border method, add 67mL EDA to 500mL double distilled water, then slowly add 350mL 6M hydrochloric acid, adjust the pH to 4.75, cool the solution to 25°C on ice, dissolve 5g BSA in 25mL double distilled water, and then slowly add this solution EDA solution was stirred continuously, 1.8 g of EDC was added, reacted at a constant temperature of 25 ° C for 2 h, and then terminated with 30 mL of acetic acid buffer solution of pH 4.75 to obtain a C-BSA solution with an increased isoelectric point. Dialyze the C-BSA solution with double-distilled water at 4°C...

Embodiment 2

[0063] The preparation of embodiment 2 hydrangea paniculata (Hydrangea paniculata Sieb) extract

[0064] Pane hydrangea, Saxifragaceae, stems were purchased from Jinxiu County, Guangxi Zhuang Autonomous Region in May 2014. Guangxi Liuzhou Forestry Bureau identified the samples. The sample specimen ID number is 4645, which currently exists in China, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.

[0065] Preparation of total coumarin glycosides from Hydrangea paniculata extract: Grind Hydrangea paniculata branches, add 10 times the amount of water to reflux and extract twice, 3 hours each time, filter the extract while it is hot, combine the filtrates, take the filtrate and balance it with water in advance The macroporous adsorption resin column (HPD100) was first used to elute the impurities with water 3 times the volume of the macromolecular polymer, and the water was discarded. Then use 17% ethanol with 5 times the volume of the macromolecular p...

Embodiment 3

[0090] Example 3 Regulate the animal experiment of chronic kidney disease intestinal flora

[0091] 1. 84 SD female mice (Speyford (Beijing) Biotechnology Co., Ltd.) were grouped into normal group, model (M) group, positive drug mycophenolate mofetil (MMF 20mg / kg) group, HP ( 7.5mg / kg, 15mg / kg, 30mg / kg) groups, 14 rats in each group, were administered orally once a day for 2 months in total, and various indicators were detected.

[0092] 2. Observation items:

[0093] (1) Functional examination: ① Quantitative determination of urine protein. ②Determination of serum creatinine, urine creatinine and serum urea nitrogen.

[0094] The results are shown in Table 2. Hydrangea paniculata extract can effectively reduce the body’s urinary albumin and serum creatinine, effectively improve renal function, and at the same time regulate the levels of total cholesterol, high-density lipoprotein, low-density lipoprotein and triglyceride in serum , regulate lipid metabolism.

[0095] (2) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a hydrangea paniculata extract in preparation of a medicine for preventing or treating chronic nephropathy, the hydrangea paniculata extract is extracted according to reflux extraction, macroporous resin ion exchange and reduced pressure distillation methods, and the hydrangea paniculata extract prevents and treats chronic nephropathy by regulating intestinal flora. The invention discloses a new mechanism for relieving chronic nephrosis by using a hydrangea paniculata extract. The hydrangea paniculata extract is applied to preparation of the medicine for regulating immune nephropathy and intestinal flora disorder caused by immune nephropathy. The hydrangea paniculata extract can effectively reduce urinary albumin and serum creatinine of an organism, effectively improve renal functions, regulate and control the levels of total cholesterol, high-density lipoprotein, low-density lipoprotein and triglyceride in serum and regulate lipid metabolism.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of Hydrangea paniculata extract in treating chronic kidney disease by regulating intestinal flora. Background technique [0002] Kidney disease is a leading cause of death worldwide, affects approximately 10% of the world's population and is increasingly recognized as a global health problem. Current treatment of early-stage chronic kidney disease (CKD) focuses on blood pressure control, reduction of protein and salt intake, prevention of acute kidney injury, and glycemic control. There is no cure or prevention strategy for CKD due to the lack of symptoms in the early stages of the disease , so timely treatment is extremely challenging. Furthermore, there is a lack of effective treatments for end-stage renal disease (ESRD) other than dialysis and kidney transplantation. Therefore, paradigm-changing concepts and innovative approaches are needed to detect, man...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/185A61K31/7048A61P13/12C12Q1/6883C12Q1/689C12Q1/04
CPCA61K36/185A61K31/7048A61P13/12C12Q1/6883C12Q1/689Y02A50/30
Inventor 张森张东明王琰马洁李昭君王伟达陈园园
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap